ライフサイエンスコーパス: GHRP

1 [azaTyr(4)]-GHRP-6 (15), [Ala(1), azaPhe(2)]-GHRP-6 (16), and [azaLeu(3), Ala(6)]-GHRP-6 (33) all exh

2 ect blocked by the GHSR1 antagonist, d-Lys-3-GHRP-6.

3 g assay using a choroid explant, [azaTyr(4)]-GHRP-6 (15), [Ala(1), azaPhe(2)]-GHRP-6 (16), and [azaLe

4 For example, [A(1), azaF(4)]- and [azaY(4)]-GHRP-6 (1a and 2b) were previously shown to bind selecti

5 alogs of growth hormone-releasing peptide 6 (GHRP-6) demonstrated a promising cluster of differentiat

6 MK-677), growth hormone-releasing peptide 6 (GHRP-6), and the 2(R)-hydroxypropyl derivative of 3-amin

7 ogues of growth hormone releasing peptide-6 (GHRP-6) exhibit promising affinity, selectivity, and mod

8 apeptide growth hormone releasing peptide-6 (GHRP-6) exhibits dual affinity for the growth hormone se

9 Phe(2)]-GHRP-6 (16), and [azaLeu(3), Ala(6)]-GHRP-6 (33) all exhibited antiangiogenic activity.

10 trations of ghrelin on the action of MK-677, GHRP-6, and L-692,585 was analyzed globally according to

11 owed that fibrinogen-like acyl-GPRP and acyl-GHRP could inhibit D.

12 To explain acyl-GPRP and acyl-GHRP inhibition of D.E association, it is proposed that

13 tered ghrelin and the synthetic GHSR agonist GHRP-2 during and/or after CSDS.

14 acy compared with the GHSR1a peptide agonist GHRP-6, and high nanomolar to low micromolar potency, de

15 -Pro-amide (GPRP) and Gly-His-Arg-Pro-amide (GHRP), respectively.

16 sequence starts with Gly-His-Arg-Pro-amide (GHRP).

17 rnal standards (triply deuterated GHRP-4 and GHRP-2 metabolite) were used to optimize the extraction

18 iation kinetics of (125)I-[His]-ghrelin, and GHRP-6 and MK-677 were able to fully displace (125)I-[Hi

19 e polymerization inhibitor peptides GPRP and GHRP.

20 nthetic peptides GPRP (knob 'A' mimetic) and GHRP (knob 'B' mimetic).

21 eritoneal injections of the GHS-R antagonist GHRP-6 [D-Lys3] prior to subsequent transfer and sucrose

22 r PF-03084014 or ghrelin receptor antagonist GHRP-6 reversed the phenotypic effects of calorie restri

23 ced the same local conformational changes as GHRP to this site.

24 atorial split-and-mix approach furnished aza-GHRP-6 leads, which were further examined by alanine sca

25 -Trp(2), Ala(3), or Trp(4) position gave aza-GHRP-6 analogues with reduced affinity toward the GHS-R1

26 Azapeptide GHRP-6 analogues have been synthesized, exhibiting micro

27 abeled internal standards (triply deuterated GHRP-4 and GHRP-2 metabolite) were used to optimize the

28 all, 28 metabolites (at least three for each GHRP) were identified from the in vivo samples and main

29 s is available and merely one metabolite for GHRP-2 is established.

30 LHRH), growth hormone releasing hexapeptide (GHRP-6), and TrpCage (sequence NLYIQWLKDGGPSSGRPPPS) yie

31 hereas the ghrelin receptor antagonist D-Lys GHRP-6 reduced plasma levels of GLP-1 and insulin and di

32 e to the GHSR1a receptor antagonist (D-Lys3)-GHRP-6 reduced ghrelin-mediated Ca(2+) channel inhibitio

33 D-Lys3-GHRP-6 and JMV 3002 also blocked ghrelin-induced increas

34 uperfusion of the GHS-R1A antagonists D-Lys3-GHRP-6 and JMV 3002 decreased evoked IPSP and mIPSC freq

35 Furthermore, D-Lys3-GHRP-6 did not affect ethanol-induced increases in IPSP

36 during or after CSDS nor chronic delivery of GHRP-2 during and after CSDS improved stress-induced dep

37 With the exemption of GHRP-2, the entity of these peptides represents nonappro

38 onferred to rEC by the peptides GPRPamide or GHRP, nor did rEC bind to a GPR peptide column.

39 cture (rfD-BbetaD432A+GH) showed the peptide GHRP was not bound to hole "b." We then re-evaluated the

40 es are the growth hormone releasing peptide (GHRP)-1, -2, -4, -5, -6, hexarelin, alexamorelin, and ip

41 ns begin with the sequence Gly-His-Arg-Pro- (GHRP-), but the homologous sequence in chicken fibrin be

42 Similarly, the lateral-association-promoting GHRP (IC30 of 1.25-1.43 mM) gave a high turbidity vs clo

43 natal rats, although to a lesser degree than GHRP-6.